<prompt> Infliximab is:IgG1 chimeric monoclonal antibody against TNF aIgG1 fully human monoclonal antibody against TNF aIgG4 chimeric monoclonal antibody against TNF aP75 TNF receptor fusion protein  <response>: Infliximab: It is a chimeric monoclonal antibody which binds and neutralizes TNF-alpha dose- 3-5 mgkg is infused i.v. every weeks. An acute reaction comprising of fever, chills, Uicaria, bronchospasm, rarely anaphylaxis may follow infusion. Susceptibility to respiratory infections is Increased and worsening of CHF has been noted. It is initially combined with Mtx which improves the response decreases antibody formation against infliximab. REF KD TRIpathi 8th ed 